Vanguard Capital Management
PCSA icon

Vanguard Capital Management’s Processa Pharmaceuticals PCSA Stock Holding History

Vanguard Capital Management’s Portfolio PCSA Stock Details PCSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$20.9K Hold
12,729
– – ﹤0.01% 3982
2026
Q2 		$24.4K Hold
12,729
– – ﹤0.01% 4003
2026
Q1 		$32.1K Buy
+12,729
New +$34.8K ﹤0.01% 3955

Other funds holding PCSA

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Jane Street
Jane Street New York $1.19T AUM 51.51% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $273B AUM 15.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Vanguard Capital Management's PCSA Position: Q3 2026 in Review

Vanguard Capital Management held its Processa Pharmaceuticals (PCSA) position steady in Q3 2026 at 12,729 shares worth $20.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3982.

Vanguard Capital Management first reported a position in PCSA in Q1 2026 and has held it in 3 quarters since. The position peaked at $32.1K in Q1 2026. 9 funds tracked by Wall St. Rank hold PCSA as of Q3 2026.

  • Vanguard Capital Management held 12,729 shares of Processa Pharmaceuticals worth $20.9K as of Q3 2026.
  • Vanguard Capital Management left its Processa Pharmaceuticals share count unchanged in Q3 2026.
  • Processa Pharmaceuticals made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #3982 holding.
  • Vanguard Capital Management first reported a position in Processa Pharmaceuticals in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Capital Management's Processa Pharmaceuticals position peaked at $32.1K in Q1 2026.
  • 9 funds tracked by Wall St. Rank held Processa Pharmaceuticals as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.